Polivy (polatuzumab vedotin-piiq)

Recently, ADCs have expanded the DLBCL therapeutic landscape, with the approvals of CD79b-targeted polatuzumab vedotin and CD19-directed loncastuximab tesirine for R/R and even frontline disease. However, the clinical application of ADCs is accompanied by challenges, including the management of characteristic toxicities, understanding and overcoming mechanisms of resistance. This review systematically synthesizes the mechanisms of action, updated clinical evidence, toxicity profiles, and resistance mechanisms of ADCs in DLBCL, while also discusses management strategies and provides perspectives on future directions.

P2, N=396, Recruiting, SWOG Cancer Research Network | Trial completion date: Dec 2029 --> Jun 2030 | Trial primary completion date: Dec 2025 --> Jun 2030

P2, N=50, Recruiting, Beijing Tongren Hospital

While novel therapies such as rituximab and polatuzumab vedotin have led to improved outcomes, approximately 35% of patients eventually develop relapsed or refractory disease. Among these, miR-155 and miR-21 are particularly well studied, playing central roles in both tumor progression and remodeling of the tumor microenvironment. This review summarizes current evidence on the biological and clinical relevance of miRNAs in DLBCL, emphasizing their diagnostic and prognostic potential.

P1, N=30, Suspended, National Cancer Institute (NCI) | Trial completion date: Jun 2026 --> Jun 2027 | Recruiting --> Suspended | Trial primary completion date: Jun 2026 --> Jun 2027

P3, N=1130, Active, not recruiting, Hoffmann-La Roche | Recruiting --> Active, not recruiting

P2, N=39, Active, not recruiting, University of Rochester | Recruiting --> Active, not recruiting

P2, N=34, Active, not recruiting, Washington University School of Medicine | Trial completion date: May 2031 --> Apr 2029 | Trial primary completion date: May 2026 --> Sep 2025

P2, N=152, Recruiting, Ruijin Hospital | Not yet recruiting --> Recruiting

This case demonstrates the diagnostic complexities of PTL with gonadal vein tumor thrombus, underscoring the importance of considering lymphoma in elderly patients with testicular masses and venous involvement. A multi-disciplinary team including urologists, hematologists, and radiation oncologists is needed to ensure appropriate therapy.

The patient received molecularly guided therapy with Pola-R-CHP (polatuzumab vedotin, rituximab, cyclophosphamide, doxorubicin, prednisone) plus venetoclax, achieving complete metabolic remission. Due to the persistent MEF2B and TET2 mutations in ctDNA indicated MRD positive, which prompted she received consolidative CAR-T therapy (axicabtagene ciloleucel)...The BCL2 inhibitor venetoclax has shown good therapeutic effects on DLBCL overexpressing BCL2. An integrated approach incorporating these strategies may improve outcomes for this rare lymphoma subtype.

P4, N=600, Recruiting, Henan Cancer Hospital; Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital